The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Open accessAbstract
Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Programmed Cell death-1 (PD-1)/Programmed death-ligand 1 (PD-L1) inhibitors. High-grade irAEs are life-threatening and often cause a severe decline in performance status in such that patients do not qualify for any further anticancer treatments. It is difficult to generalize the evidence in the current literature on risk factors or biomarkers for the entire class of ICIs as the studies so far are either disease-specific (e.g., lung cancer or melanoma) or ICI agent-specific (e.g., pembrolizumab, ipilimumab) or irAE-specific (e.g., pneumonitis or gastritis). In this review, risk factors and biomarkers to consider before initiating or monitoring ICI are listed with a practical purpose in day-to-day practice. Risk factors are grouped into demographics and social history, medical history, and medication history, tumor-specific and agent-specific risk factors. A higher risk of irAE is associated with age <60 years, high body mass index, women on CTLA4 and men on PD-1/PD-L1 agents, and chronic smokers. Patients with significant kidney (Stage IV-V), cardiac (heart failure, coronary artery disease, myocardial infarction, hypertension), and lung (asthma, pulmonary fibrosis, and chronic obstructive pulmonary disease) are at a higher risk of respective organ-specific irAEs. Pre-existing autoimmune disease and chronic use of certain drugs (proton pump inhibitors, diuretics, anti-inflammatory drugs) also increase the irAE-risk. Biomarkers are categorized into circulating blood counts, cytokines, autoantibodies, HLA genotypes, microRNA, gene expression profiling, and serum proteins. The blood counts and certain protein markers (albumin and thyroid-stimulating hormone) are readily accessible in current practice. High neutrophil-lymphocyte ratio, eosinophil/monocyte/lymphocyte counts; TSH and troponins at diagnosis and drop in the white count and lymphocyte count can predict irAE. Other biomarkers with limited evidence are cytokines, autoantibodies, HLA genotypes, microRNA, and gene expression profiling. With fast-expanding approvals for ICIs in various cancer types, knowledge on risk factors and biomarkers can help providers assess the irAE-risk of their patients. Prospective disease and agent-specific studies are needed to provide further insight on this essential aspect of ICI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
RetractedAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Ranade, V. V. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31817c941f · Cited by 2,775
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.0006 · Cited by 1,071 · cited 2×
“Resume same agent: After complete recovery from irAE (34, 135, 139)”
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“When the intestinal microbiota (through16S ribosomal RNA sequencing) was analyzed in 34 MM patients treated with Ipilumimab, an abundance of microbes from the Bacteroidetes phylum, specifically Bacteroidaceae, Rikenellaceae, and Barnesiellaceae is associated with reduced risk of irAE-GI (colitis) (121).”
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 939
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · cited 1×
“Rechallenge Class switch: PD-1/PD-L1 to CTLA4, vice versa (43, 138)”
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri3108 · Cited by 786
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590 · cited 1×
“reviewed HLA typing of patients who developed ICI-induced autoimmune insulindependent diabetes and reported that HLA-DR4 is frequently (76%) associated with it (114).”
Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 574
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
Proctor, M. J., McMillan, D. C., Morrison, D. S., Fletcher, C. D., Horgan, P. G., & Clarke, S. J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.292 · Cited by 508
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494
Joshi, S., Pantalena, L.-C., Liu, X. K., Gaffen, S. L., Liu, H., Rohowsky-Kochan, C., Ichiyama, K., Yoshimura, A., Steinman, L., Christakos, S., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05020-11 · Cited by 458
The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T Cells
Amarnath, S., Mangus, C. W., Wang, J. C. M., Wei, F., He, A., Kapoor, V., Foley, J. E., Massey, P. R., Felizardo, T. C., Riley, J. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003130 · Cited by 446
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00050-2017 · Cited by 412
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
Cortazar, F. B., Kibbelaar, Z. A., Glezerman, I. G., Abudayyeh, A., Mamlouk, O., Motwani, S. S., Murakami, N., Herrmann, S. M., Manohar, S., Shirali, A. C., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019070676 · Cited by 407
Tarhini, A. A., Zahoor, H., Lin, Y., Malhotra, U., Sander, C., Butterfield, L. H., & Kirkwood, J. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0081-1 · Cited by 394
Pollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx642 · Cited by 393 · cited 1×
“Resume same agent: After complete recovery from irAE (34, 135, 139)”
Lim, S. Y., Lee, J. H., Gide, T. N., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E. J., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2795 · Cited by 381
Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0498 · Cited by 359
Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 353
Toi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 342
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0305 · Cited by 341 · cited 1×
“Contrary to most studies, a small study with 56 NSCLCs treated with PD-1 inhibitors, the incidence of irAE was not that different from the trials that excluded patients with AD (76).”
Santini, F. C., Rizvi, H., Plodkowski, A. J., Ni, A., Lacouture, M. E., Gambarin-Gelwan, M., Wilkins, O., Panora, E., Halpenny, D. F., Long, N. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0755 · Cited by 331
Seethapathy, H., Zhao, S., Chute, D. F., Zubiri, L., Oppong, Y., Strohbehn, I., Cortazar, F. B., Leaf, D. E., Mooradian, M. J., Villani, A.-C., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00990119 · Cited by 304
Dougan, M., Wang, Y., Rubio-Tapia, A., & Lim, J. K. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.063 · Cited by 292
Shirali, A. C., Perazella, M. A., & Gettinger, S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.057 · Cited by 284
Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function
Whelton, A., & Hamilton, C. W. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb03743.x · Cited by 282
Immune checkpoint inhibitor-induced colitis: A comprehensive review
Som, A., Mandaliya, R., Alsaadi, D., Farshidpour, M., Charabaty, A., Malhotra, N., & Mattar, M. C. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i4.405 · Cited by 265
Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2324 · Cited by 236
Pavan, A., Calvetti, L., Dal Maso, A., Attili, I., Del Bianco, P., Pasello, G., Guarneri, V., Aprile, G., Conte, P., & Bonanno, L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0563 · Cited by 235
Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities
Tahir, S. A., Gao, J., Miura, Y., Blando, J., Tidwell, R. S. S., Zhao, H., Subudhi, S. K., Tawbi, H., Keung, E., Wargo, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908079116 · Cited by 235
Weinmann, S. C., & Pisetsky, D. S. (2019) · Rheumatology · doi:10.1093/rheumatology/kez308 · Cited by 234
Subudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226 · cited 2×
“Similarly, expansion of CD8 T-cell clones (≥ 55) has 100% sensitivity of occurrence of irAE (G2-G3) (94).”
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Wang, F., Yin, Q., Chen, L., & Davis, M. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712901115 · Cited by 223
Abu-Sbeih, H., Ali, F. S., Luo, W., Qiao, W., Raju, G. S., & Wang, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0411-1 · Cited by 209
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Abu-Sbeih, H., Faleck, D. M., Ricciuti, B., Mendelsohn, R. B., Naqash, A. R., Cohen, J. V., Sellers, M. C., Balaji, A., Ben-Betzalel, G., Hajir, I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01674 · Cited by 204
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1467-x · Cited by 201 · cited 2×
“Men were at high risk of pulmonary toxicity with PD-1/ PD-L1 inhibitors (in multiple cancers including MM and lung cancer), while women are at high risk with CTLA-4 inhibitors (in MM) (33, 34).”
Meraz-Muñoz, A., Amir, E., Ng, P., Avila-Casado, C., Ragobar, C., Chan, C., Kim, J., Wald, R., & Kitchlu, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000467 · Cited by 194
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Betof, A. S., Nipp, R. D., Giobbie-Hurder, A., Johnpulle, R. A. N., Rubin, K., Rubinstein, S. M., Flaherty, K. T., Lawrence, D. P., Johnson, D. B., & Sullivan, R. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0450 · Cited by 191
Abu-Sbeih, H., Ali, F. S., Wang, X., Mallepally, N., Chen, E., Altan, M., Bresalier, R. S., Charabaty, A., Dadu, R., Jazaeri, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0577-1 · Cited by 191
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali, O., Berner, F., Bomze, D., Fässler, M., Diem, S., Cozzio, A., Jörger, M., Früh, M., Driessen, C., Lenz, T. L., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.009 · Cited by 187
Daly, L. E., Power, D. G., O'Reilly, Á., Donnellan, P., Cushen, S. J., O'Sullivan, K., Twomey, M., Woodlock, D. P., Redmond, H. P., & Ryan, A. M. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.431 · Cited by 187
Immune dysregulation in cancer patients developing immune-related adverse events
Khan, S., Khan, S. A., Luo, X., Fattah, F. J., Saltarski, J., Gloria-McCutchen, Y., Lu, R., Xie, Y., Li, Q., Wakeland, E., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0155-1 · Cited by 186
Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer
Atchley, W. T., Alvarez, C., Saxena-Beem, S., Schwartz, T. A., Ishizawar, R. C., Patel, K. P., & Rivera, M. P. (2021) · Chest · doi:10.1016/j.chest.2021.02.032 · Cited by 186
The T-cell-receptor signaling network
Huse, M. (2009) · Journal of Cell Science · doi:10.1242/jcs.042762 · Cited by 183
Shahabi, V., Berman, D., Chasalow, S. D., Wang, L., Tsuchihashi, Z., Hu, B., Panting, L., Jure-Kunkel, M., & Ji, R.-R. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-75 · Cited by 173
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Eun, Y., Kim, I. Y., Sun, J.-M., Lee, J., Cha, H.-S., Koh, E.-M., Kim, H., & Lee, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50574-6 · Cited by 171
Chu, X., Zhao, J., Zhou, J., Zhou, F., Jiang, T., Jiang, S., Sun, X., You, X., Wu, F., Ren, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.015 · Cited by 164
Al‐Aly, Z., Maddukuri, G. S., & Xie, Y. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.07.012 · Cited by 159
Duhen, R., Ballesteros‐Merino, C., Frye, A. K., Tran, E., Rajamanickam, V., Chang, S., Koguchi, Y., Bifulco, C. B., Bernard, B. M., Leidner, R. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21383-1 · Cited by 156
Ascierto, P. A., Bono, P., Bhatia, S., Melero, I., Nyakas, M., Svane, I. M., Larkin, J., Gomez‐Roca, C., Schadendorf, D., Dummer, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.011 · Cited by 150
Kanai, O., Kim, Y. H., Demura, Y., Kanai, M., Ito, T., Fujita, K., Yoshida, H., Akai, M., Mio, T., & Hirai, T. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12759 · Cited by 144
Allouchery, M., Lombard, T., Martin, M., Rouby, F., Sassier, M., Bertin, C., Atzenhoffer, M., Miremont‐Salamé, G., Pérault‐Pochat, M., & Puyade, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001622 · Cited by 144
Laubli, H. P., Balmelli, C., Kaufmann, L., Stanczak, M. A., Syedbasha, M., Vogt, D., Hertig, A., Müller, B. P., Gautschi, O. P., Stenner, F., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0353-7 · Cited by 142
Bowyer, S. E., Prithviraj, P., Lorigan, P. C., Larkin, J., McArthur, G. A., Atkinson, V. G., Millward, M., Khou, M., Diem, S., Ramanujam, S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.107 · Cited by 139
Bomze, D., Hasan Ali, O., Bate, A., & Flatz, L. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3221 · Cited by 129
Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis.
Callahan, M. K., Yang, A., Tandon, S., Xu, Y., Subudhi, S. K., Roman, R., Heine, A. I., Pogoriler, E., Kuk, D., Panageas, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2505 · Cited by 129
Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 128
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
Kartolo, A., Sattar, J., Sahai, V., Baetz, T. D., & Lakoff, J. M. (2018) · Current Oncology · doi:10.3747/co.25.4047 · Cited by 124
Cui, P., Liu, Z., Wang, G., Ma, J., Qian, Y., Zhang, F., Han, C., Long, Y., Li, Y., Zheng, X., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1579 · Cited by 122
Wongvibulsin, S., Pahalyants, V., Kalinich, M., Murphy, W., Yu, K., Wang, F., Chen, S. T., Reynolds, K. L., Kwatra, S. G., & Semenov, Y. R. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.094 · Cited by 122
Nakamura, Y., Tanaka, R., Maruyama, H., Ishitsuka, Y., Okiyama, N., Watanabe, R., Fujimoto, M., & Fujisawa, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy201 · Cited by 114
Fujisawa, Y., Yoshino, K., Otsuka, A., Funakoshi, T., Fujimura, T., Yamamoto, Y., Hata, H., Gosho, M., Tanaka, R., Yamaguchi, K., et al. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.07.007 · Cited by 113
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 113
Cappelli, L. C., Dorak, M. T., Bettinotti, M. P., Bingham, C. O., & Shah, A. A. (2019) · Rheumatology · doi:10.1093/rheumatology/key358 · Cited by 111
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors
Chong, C. R., Park, V. J., Cohen, B., Postow, M. A., Wolchok, J. D., & Kamboj, M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz202 · Cited by 111
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
C-reactive protein as an early marker of immune-related adverse events
Abolhassani, A.-R., Schuler, G., Kirchberger, M. C., & Heinzerling, L. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03002-1 · Cited by 107
Ali, O. H., Bomze, D., Ring, S. S., Berner, F., Fässler, M., Diem, S., Abdou, M.-T., Hammers, C. M., Emtenani, S., Braun, A., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.08.045 · Cited by 106
Michailidou, D., Khaki, A. R., Morelli, M. P., Diamantopoulos, L. N., Singh, N., & Grivas, P. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-88307-3 · Cited by 102
Shibaki, R., Murakami, S., Matsumoto, Y., Yoshida, T., Goto, Y., Kanda, S., Horinouchi, H., Fujiwara, Y., Yamamoto, N., Kusumoto, M., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02431-8 · Cited by 101
Yano, S., Ashida, K., Sakamoto, R., Sakaguchi, C., Ogata, M., Maruyama, K., Sakamoto, S., Ikeda, M., Ohe, K., Akasu, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.049 · Cited by 101
Fujimura, T., Sato, Y., Tanita, K., Kambayashi, Y., Otsuka, A., Fujisawa, Y., Yoshino, K., Matsushita, S., Funakoshi, T., Hata, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24509 · Cited by 100
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
Marschner, D., Falk, M., Jávorniczky, N. R., Hanke, K., Rawluk, J. K., Schmitt-Graeff, A. H., Simonetta, F., Haring, E., Dicks, S., Ku, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132334 · Cited by 98
Lee, P. Y., Oen, K. Q. X., Lim, G. R. S., Hartono, J. L., Muthiah, M. D., Huang, D. Q., Teo, F. S. W., Li, A., Mak, A., Chandran, N. S., et al. (2021) · Cancers · doi:10.3390/cancers13061308 · Cited by 98
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 96
(IMI), O. B. O. T. I. M. I., Pistillo, M. P., Fontana, V., Morabito, A., Dozin, B., Laurent, S., Carosio, R., Banelli, B., Ferrero, F., Spano, L., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2258-1 · Cited by 92
Guzmán-Prado, Y., Shimol, J. B., & Samson, O. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02663-z · Cited by 91
Kalinich, M., Murphy, W., Wongvibulsin, S., Pahalyants, V., Yu, K., Lu, C., Wang, F., Zubiri, L., Naranbhai, V., Gusev, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001935 · Cited by 91
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Triggianese, P., Novelli, L., Galdiero, M. R., Chimenti, M. S., Conigliaro, P., Perricone, R., Perricone, C., & Gerli, R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102590 · Cited by 87
Kang, D. H., Park, C., Chung, C., Oh, I., Kim, Y., Park, D., Kim, J., Kwon, G. C., Kwon, I., Sun, P., et al. (2020) · Immune Network · doi:10.4110/in.2020.20.e27 · Cited by 87
Impact of age on the toxicity of immune checkpoint inhibition
Samani, A., Zhang, S., Spiers, L., Suwaidan, A. A., Merrick, S., Tippu, Z., Payne, M., Faust, G. E. S., Papa, S., Fields, P. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000871 · Cited by 86
Tran, B., Carvajal, R. D., Marabelle, A., Patel, S. P., LoRusso, P. M., Rasmussen, E., Juan, G., Upreti, V. V., Beers, C., Ngarmchamnanrith, G., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0407-x · Cited by 84
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 81
Zou, F., Wang, X., Oliva, I. C. G., McQuade, J. L., Wang, J. R., Zhang, H. C., Thompson, J. A., Thomas, A. S., & Wang, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002058 · Cited by 81
Okada, N., Matsuoka, R., Sakurada, T., Goda, M., Chuma, M., Yagi, K., Zamami, Y., Nishioka, Y., & Ishizawa, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70743-2 · Cited by 80
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study
Espi, M., Teuma, C., Novel-Catin, E., Maillet, D., Souquet, P. J., Dalle, S., Koppe, L., & Fouque, D. P. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.005 · Cited by 77
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 76
Manohar, S., Ghamrawi, R., Chengappa, M., Goksu, B. N. B., Kottschade, L. A., Finnes, H. D., Dronca, R. S., Leventakos, K., Herrmann, J., & Herrmann, S. M. (2020) · Kidney360 · doi:10.34067/kid.0000152019 · Cited by 74
Oyanagi, J., Koh, Y., Sato, K., Mori, K. P., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.020 · Cited by 73
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01002-w · Cited by 71
Abdel‐Wahab, N., Diab, A. K., Yu, R. K., Futreal, P. A., Criswell, L. A., Tayar, J. H., Dadu, R., Shannon, V. R., Shete, S. S., & Suarez-Almazor, M. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02797-0 · Cited by 70
Tyan, K., Bagińska, J., Brainard, M., Giobbie‐Hurder, A., Severgnini, M., Manos, M. P., Haq, R., Buchbinder, E. I., Ott, P. A., Hodi, F. S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02855-1 · Cited by 68
Wijn, D. H., Groeneveld, G. H., Vollaard, A. M., Muller, M., Wallinga, J., Gelderblom, H. A. J., & Smit, E. F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.012 · Cited by 67
Dankers, W., Davelaar, N., van Hamburg, J. P., van de Peppel, J., Colin, E. M., & Lubberts, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01504 · Cited by 61
Isono, T., Kagiyama, N., Takano, K., Hosoda, C., Nishida, T., Kawate, E., Kobayashi, Y., Ishiguro, T., Takaku, Y., Kurashima, K., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13736 · Cited by 60
Molina, G. E., Zubiri, L., Cohen, J. V., Durbin, S., Petrillo, L. A., Allen, I. M., Murciano‐Goroff, Y. R., Dougan, M. L., Thomas, M. F., Faje, A. T., et al. (2021) · The Oncologist · doi:10.1002/onco.13740 · Cited by 58
Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy
Luongo, C., Morra, R. P., Gambale, C., Porcelli, T., Sessa, F., Matano, E., Damiano, V., Klain, M., Schlumberger, M. J., & Salvatore, D. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01508-5 · Cited by 57
Siu, L. L., Steeghs, N., Meniawy, T. M., Joerger, M., Spratlin, J. L., Rottey, S., Nagrial, A. M., Cooper, A. J., Meier, R., Guan, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.104 · Cited by 55
PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity
Aktürk, H. K., Alkanani, A. K., Zhao, Z., Yu, L., & Michels, A. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01430 · Cited by 54
Brilli, L., Danielli, R., Campanile, M., Secchi, C., Ciuoli, C., Calabrò, L., Pilli, T., Cartocci, A., Pacini, F., Giacomo, A. M. D., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01480-6 · Cited by 53
Tang, H. J., Zhou, J., & Bai, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625872 · Cited by 50
Peng, W., Williams, L. J., Xu, C., Melendez, B., McKenzie, J. A., Chen, Y., Jackson, H. L., Voo, K. S., Mbofung, R. M., Leahey, S. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1259 · Cited by 49
Coureau, M., Meert, A., Berghmans, T., & Grigoriu, B. D. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00137 · Cited by 48
Yoon, J. H., Hong, A. R., Kim, H. K., & Kang, H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.906 · Cited by 48
Sakata, Y., Kawamura, K., Ichikado, K., Shingu, N., Yasuda, Y. U., Eguchi, Y., Anan, K., Hisanaga, J., Nitawaki, T., Iio, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.02.011 · Cited by 47
Hirashima, T., Kanai, T., Suzuki, H., Yoshida, H., MATSUSHITA, A., KAWASUMI, H., Samejima, Y., Noda, Y., Nasu, S., Tanaka, A., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13832 · Cited by 47
Biewenga, M., van der Kooij, M. K., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Boers‐Sonderen, M. J., Hospers, G. A. P., Piersma, D., van Rijn, R. S., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10151-4 · Cited by 45
Zhao, L., Li, Y., Jiang, N., Song, X., Xu, J., Zhu, X., Chen, C., Kong, C., Wang, X., Zong, D., et al. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000415 · Cited by 39
Lal, J. C., Brown, S.-A. N., Collier, P. H., & Cheng, F. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00106-x · Cited by 36
Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy
Félix, J., Cassinat, B., Porcher, R., Schlageter, M., Maubec, E., Pagès, C., Baroudjian, B., Homyrda, L., Boukouaci, W., Tamouza, R., et al. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.09.030 · Cited by 35
Inaba, H., Kaido, Y., Ito, S., Hirobata, T., Inoue, G., Sugita, T., Yamamoto, Y., Jinnin, M., Kimura, H. J., Kobayashi, T., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1282 · Cited by 34
Allouchery, M., Beuvon, C., Pérault‐Pochat, M., Roblot, P., Puyade, M., & Martin, M. (2022) · Cancers · doi:10.3390/cancers14040955 · Cited by 33
The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis
Asada, M., Mikami, T., Niimura, T., Zamami, Y., Uesawa, Y., Chuma, M., & Ishizawa, K. (2021) · Oncology · doi:10.1159/000512633 · Cited by 32
Human Leukocyte Antigen (HLA) Typing by DNA Sequencing
Lázaro, A. M. P., Tu, B., Yang, R., Xiao, Y., Kariyawasam, K., Ng, J., & Hurley, C. K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-493-7_9 · Cited by 31
Metabolic disease and adverse events from immune checkpoint inhibitors
Leiter, A., Carroll, E., Alwis, S. D., Brooks, D., Shimol, J. B., Eisenberg, E., Wisnivesky, J. P., Galsky, M. D., & Gallagher, E. J. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1362 · Cited by 31
Shimozaki, K., Sukawa, Y., Sato, Y., Horie, S., Chida, A., Tsugaru, K., Togasaki, K., Kawasaki, K., Hirata, K., Hayashi, H., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-0861 · Cited by 31
Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors
Sun, L., Arbesman, J., & Piliang, M. P. (2020) · Archives of Dermatological Research · doi:10.1007/s00403-020-02094-x · Cited by 25
Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis
Sher, A. F., Golshani, G. M., & Wu, S. (2020) · Cancer Investigation · doi:10.1080/07357907.2020.1721521 · Cited by 23
Fujiwara, Y., Horita, N., Namkoong, H., & Galsky, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.012 · Cited by 23
Manne, A., Mulekar, M. S., Escobar, D. E., Alsayed, A., Sharma, G., Prodduturvar, P., Khushman, M. M., Howard, J. H., Gilbert, R., & Alkharabsheh, O. A. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4511 · Cited by 20
Self-citationTan, B., Chen, M., Guo, Q., Tang, H., Li, Y., Jia, X., Xu, Y., Zhu, L., Wang, M., & Qian, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13990 · Cited by 19
Seethapathy, H. S., Street, S., Strohbehn, I. A., Lee, M. D., Zhao, S. H., Rusibamayila, N., Chute, D. F., Gao, X. Y., Michaelson, M. D., Rahma, O. E., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.031 · Cited by 17
Johns, A. C., Yang, M., Wei, L., Grogan, M. M., Patel, S. H., Li, M., Husain, M., Kendra, K. L., Otterson, G. A., Burkart, J. T., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03371-0 · Cited by 14
Self-citationImmune‐related adverse events in cancer patients being treated with immune checkpoint inhibitors
Byrne, M. M., Lucas, M., Pai, L. H., Breeze, J. L., & Parsons, S. K. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13703 · Cited by 13
Qin, Z., Liu, K., Xu, X., Li, T., Ge, Y., Wu, B., Xing, C., & Mao, H. (2022) · Future Oncology · doi:10.2217/fon-2021-1004 · Cited by 13
Kazama, S., Morimoto, R., Kimura, Y., Shibata, N., Ozaki, R., Araki, T., Mizutani, T., Oishi, H., Arao, Y., Kuwayama, T., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00112-z · Cited by 9
Gehlot, P., & Holoshitz, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.06013-6 · Cited by 5
Tyan, K., Bagińska, J., Brainard, M., Giobbie‐Hurder, A., Severgnini, M., Manos, M. P., Haq, R., Buchbinder, E. I., Ott, P. A., Hodi, F. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-sitc2020.0648 · Cited by 5
Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.
Golshani, G. M., Sher, A. F., & Wu, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2561 · Cited by 2
Cardeña-Gutiérrez, A., Mielgo-Rubio, X., Muñoz, M. R., Cabañes, R. M., Muñoz, D. M., Polo, S. H., Olier, C., Nuño, A. H., Peña, V. S., Becerra, M. V. S., et al. (2021) · F1000Research · doi:10.12688/f1000research.53327.1 · Cited by 1
Cited by
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., et al. (2023) · Cancers · doi:10.3390/cancers15051629 · Cited by 100
Metadata
- Authors
- Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J., & Manne, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-04-26
- Volume
- 13
- Pages
- 779691-779691
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4285742057
- Cited by
- 344
- References
- 137
- FWCI
- 26.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.